Novartis Projects 5% Annual Sales Growth Through 2031, Core Operating Margin to Recover Above 40% by 2029

Deep News15:00

On November 19, Swiss pharmaceutical giant Novartis AG (NVS) released its latest medium- to long-term performance outlook, projecting that sales will maintain an average annual growth rate of 5% through 2031 at constant exchange rates, with the core operating margin expected to recover to 40% or above by 2029.

Although the heart failure treatment Entresto faces generic competition, putting pressure on the company's profitability, Novartis AG (NVS) CEO Vas Narasimhan said the company is expected to continue achieving business growth while navigating the largest wave of drug patent expirations in its history in 2026.

Raises Sales Forecasts for Three Core Drugs

Novartis AG (NVS) raised its peak annual sales forecasts for three drugs: Kesimpta, from $6 billion to $8 billion; Scemblix, from $4 billion to $5 billion; and Leqvio, from $4 billion to $5 billion.

Previously, Novartis AG (NVS) had also raised its peak annual sales forecast for Rhapsido (Remibrutinib) to $8 billion, covering indications such as chronic spontaneous urticaria, chronic inducible urticaria, and relapsing multiple sclerosis.

Currently, Novartis AG (NVS) has nine marketed drugs or product lines with peak annual sales potential of $3 billion to $10 billion, namely Kisqali, Rhapsido, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, the Zolgensma series (including Zolgensma and Itvisma), and Fabhalta.

Rich R&D Pipeline Supports Long-Term Growth

Novartis AG (NVS) expects to announce more than 35 clinical trial results by 2031 that could support regulatory approval applications.

Currently, the company's R&D pipeline contains more than 30 candidate drugs with high commercial value potential, of which more than 20 are in registration, Phase II, or Phase III clinical trials, and more than 10 are in or about to enter Phase I clinical trials.

In addition, 10 drugs in late-stage development are expected to achieve peak annual sales in the billions of dollars.

Key investigational drugs that Novartis AG (NVS) is focusing on include Abelacimab for preventing stroke in patients with atrial fibrillation, QCZ484 for treating hypertension, Pelabresib for treating myelofibrosis, and 225Ac-PSMA-617 for treating prostate cancer.

Novartis AG (NVS) believes that its existing marketed drugs and R&D pipeline together will support the company in achieving mid-single-digit sales growth over the long term.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment